Articles tagged ‘anticoagulants’

Novel oral anticoagulants (NOACs) are associated with an overall clinical benefit compared with vitamin K antagonists, according to a study¹ published recently in Circulation.

Oral anticoagulant (OAC) use in patients with atrial fibrillation (AF) has increased in UK practice since 2007, but remains suboptimal in current practice, according to a study1 published recently in the British Journal of General Practice.

Novel oral anticoagulants (NOACs) are associated with an overall clinical benefit compared with vitamin K antagonists, according to a study¹ published recently in Circulation.

Three approaches may reverse the activity of the new oral anticoagulant apixaban, when a person needs emergency surgery, for example, according to laboratory research presented in the American Heart Association’s Emerging Science Series webinar.¹

A new oral anticoagulant, dabigatran etexilate (Pradaxa®, Boehringer Ingelheim), has been made available in the UK. Following the EU licence for dabigatran, granted on 1st August 2011,¹ a recommended dose of 150 mg twice daily is now licensed in the UK for the prevention of stroke and systemic embolism in eligible adult patients with AF.

The superiority of dabigatran to warfarin, as reported by the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, may be offset by its cost, according to an editorial¹ published recently in Circulation.